用vedolizumab治疗的炎症性肠病患者的急性间歇性炎:一个系统性审查
Anders Forss1,2, Paulina Flis3,4, Adonis Sotoodeh1
1Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
作为整合素抑制剂的维多利祖马布在炎症性肠病 (IBD) 患者中很少会引起急性间歇性炎 (AIN). 监测功能对于早期发现和预防永久性损伤至关重要.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 急性间歇性炎 (AIN) 是一种潜在的药物并发症,导致损伤.
- 维多利祖马布是一种整合素抑制剂,用于炎症性肠病 (IBD).
- 已在接受vedolizumab治疗的IBD患者中报告了AIN.
结论:
- 维多利祖马布在IBD患者中可能很少引起AIN.
- 意识到AIN症状和实验室发现是必不可少的.
- 建议对接受vedolizumab的IBD患者进行定期功能监测.
更多相关视频
07:05Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
Published on: December 15, 2017
08:27Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
Published on: September 20, 2018
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease I: Introduction
Inflammatory Bowel Disease III: Crohn's Disease
Inflammatory Bowel Disease IV: Clinical Manifestations
